服用奥利戈平对多囊卵巢综合征(PCOS)女性卵巢形态的影响

IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL International Journal of Clinical Practice Pub Date : 2024-06-12 DOI:10.1155/2024/6479885
Sayed Mahmoud Sajjadi-Jazi, Milad Sanginabadi, Behnaz Moradi, Amir Pejman Hashemi Taheri, Mehrnam Amouei, Mostafa Qorbani, Saeed Hosseini, Masoumeh Gity, Mohammad Reza Mohajeri-Tehrani, Seyed Vahid Taheri, Asieh Mansour
{"title":"服用奥利戈平对多囊卵巢综合征(PCOS)女性卵巢形态的影响","authors":"Sayed Mahmoud Sajjadi-Jazi,&nbsp;Milad Sanginabadi,&nbsp;Behnaz Moradi,&nbsp;Amir Pejman Hashemi Taheri,&nbsp;Mehrnam Amouei,&nbsp;Mostafa Qorbani,&nbsp;Saeed Hosseini,&nbsp;Masoumeh Gity,&nbsp;Mohammad Reza Mohajeri-Tehrani,&nbsp;Seyed Vahid Taheri,&nbsp;Asieh Mansour","doi":"10.1155/2024/6479885","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Background</i>. The effects of oligopin as an antioxidant on polycystic ovarian morphology (PCOM) have not yet been examined. Therefore, the objective of this study was to evaluate the oligopin supplementation on PCOM among patients with polycystic ovarian syndrome (PCOS). <i>Methods</i>. This randomized, placebo-controlled trial was carried out at Shariati Hospital, Arash Hospital, and Yas Hospital, Tehran, Iran, to determine the effect of oligopin (50 mg/d) or placebo in PCOS patients. The ultrasonographic ovarian morphology was assessed in women aged 18–40 years, before and after 3 months of intervention. <i>Results</i>. Among 45 randomized participants, 32 participants, of whom 17 were in the oligopin group and 15 were in the placebo group completed the trial. There was only one adverse event in the oligopin group. The mean (standard deviation) age of the patients was 30.47 (6.30) years and the median (interquartile range) BMI was 27.50 (23.42–33.55). Three months of oligopin therapy significantly decreased ovarian stromal area (<i>p</i> = 0.01) and stromal/total area (<i>p</i> = 0.003). However, no significant differences were observed in the ovarian volume, ovarian area, 2–9 mm antral follicle counts, or peripheral follicle distribution pattern at 3 months. <i>Conclusion</i>. Among participants with PCOS, the use of oligopin (50 mg) daily, as compared with a placebo, resulted in improvement of the stromal area and stromal/total area at the end of the 3 months of treatment. Further studies are, however, needed to evaluate the longer-term efficacy and safety. This trial is registered with IRCT20140406017139N3.</p>\n </div>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2024 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/6479885","citationCount":"0","resultStr":"{\"title\":\"Effect of Oligopin Administration on Ovarian Morphology in Women with Polycystic Ovarian Syndrome (PCOS)\",\"authors\":\"Sayed Mahmoud Sajjadi-Jazi,&nbsp;Milad Sanginabadi,&nbsp;Behnaz Moradi,&nbsp;Amir Pejman Hashemi Taheri,&nbsp;Mehrnam Amouei,&nbsp;Mostafa Qorbani,&nbsp;Saeed Hosseini,&nbsp;Masoumeh Gity,&nbsp;Mohammad Reza Mohajeri-Tehrani,&nbsp;Seyed Vahid Taheri,&nbsp;Asieh Mansour\",\"doi\":\"10.1155/2024/6479885\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><i>Background</i>. The effects of oligopin as an antioxidant on polycystic ovarian morphology (PCOM) have not yet been examined. Therefore, the objective of this study was to evaluate the oligopin supplementation on PCOM among patients with polycystic ovarian syndrome (PCOS). <i>Methods</i>. This randomized, placebo-controlled trial was carried out at Shariati Hospital, Arash Hospital, and Yas Hospital, Tehran, Iran, to determine the effect of oligopin (50 mg/d) or placebo in PCOS patients. The ultrasonographic ovarian morphology was assessed in women aged 18–40 years, before and after 3 months of intervention. <i>Results</i>. Among 45 randomized participants, 32 participants, of whom 17 were in the oligopin group and 15 were in the placebo group completed the trial. There was only one adverse event in the oligopin group. The mean (standard deviation) age of the patients was 30.47 (6.30) years and the median (interquartile range) BMI was 27.50 (23.42–33.55). Three months of oligopin therapy significantly decreased ovarian stromal area (<i>p</i> = 0.01) and stromal/total area (<i>p</i> = 0.003). However, no significant differences were observed in the ovarian volume, ovarian area, 2–9 mm antral follicle counts, or peripheral follicle distribution pattern at 3 months. <i>Conclusion</i>. Among participants with PCOS, the use of oligopin (50 mg) daily, as compared with a placebo, resulted in improvement of the stromal area and stromal/total area at the end of the 3 months of treatment. Further studies are, however, needed to evaluate the longer-term efficacy and safety. This trial is registered with IRCT20140406017139N3.</p>\\n </div>\",\"PeriodicalId\":13782,\"journal\":{\"name\":\"International Journal of Clinical Practice\",\"volume\":\"2024 1\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/6479885\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2024/6479885\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/6479885","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景。低聚果糖作为一种抗氧化剂对多囊卵巢形态(PCOM)的影响尚未得到研究。因此,本研究旨在评估多囊卵巢综合征(PCOS)患者补充低聚果糖对 PCOM 的影响。研究方法这项随机安慰剂对照试验在伊朗德黑兰的沙里亚提医院、阿拉什医院和亚斯医院进行,以确定低聚果糖(50 毫克/天)或安慰剂对多囊卵巢综合征患者的影响。在干预 3 个月前后,对 18-40 岁女性的卵巢超声形态进行了评估。结果显示在45名随机参与者中,有32人完成了试验,其中寡肽组17人,安慰剂组15人。寡肽组仅发生了一起不良事件。患者的平均年龄(标准差)为30.47(6.30)岁,体重指数中位数(四分位数间距)为27.50(23.42-33.55)。寡肽治疗三个月后,卵巢基质面积(p = 0.01)和基质/总面积(p = 0.003)明显减少。然而,3个月后,卵巢体积、卵巢面积、2-9毫米前卵泡计数或外周卵泡分布模式均无明显差异。结论在患有多囊卵巢综合症的参与者中,与安慰剂相比,每天服用寡肽(50 毫克)可在 3 个月治疗结束时改善基质面积和基质/总面积。不过,还需要进一步的研究来评估其长期疗效和安全性。该试验已注册为 IRCT20140406017139N3。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effect of Oligopin Administration on Ovarian Morphology in Women with Polycystic Ovarian Syndrome (PCOS)

Background. The effects of oligopin as an antioxidant on polycystic ovarian morphology (PCOM) have not yet been examined. Therefore, the objective of this study was to evaluate the oligopin supplementation on PCOM among patients with polycystic ovarian syndrome (PCOS). Methods. This randomized, placebo-controlled trial was carried out at Shariati Hospital, Arash Hospital, and Yas Hospital, Tehran, Iran, to determine the effect of oligopin (50 mg/d) or placebo in PCOS patients. The ultrasonographic ovarian morphology was assessed in women aged 18–40 years, before and after 3 months of intervention. Results. Among 45 randomized participants, 32 participants, of whom 17 were in the oligopin group and 15 were in the placebo group completed the trial. There was only one adverse event in the oligopin group. The mean (standard deviation) age of the patients was 30.47 (6.30) years and the median (interquartile range) BMI was 27.50 (23.42–33.55). Three months of oligopin therapy significantly decreased ovarian stromal area (p = 0.01) and stromal/total area (p = 0.003). However, no significant differences were observed in the ovarian volume, ovarian area, 2–9 mm antral follicle counts, or peripheral follicle distribution pattern at 3 months. Conclusion. Among participants with PCOS, the use of oligopin (50 mg) daily, as compared with a placebo, resulted in improvement of the stromal area and stromal/total area at the end of the 3 months of treatment. Further studies are, however, needed to evaluate the longer-term efficacy and safety. This trial is registered with IRCT20140406017139N3.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
274
审稿时长
3-8 weeks
期刊介绍: IJCP is a general medical journal. IJCP gives special priority to work that has international appeal. IJCP publishes: Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion] Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion] Study design and interpretation. Example. [Always peer reviewed] Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed] Meta-analyses. [Always peer reviewed] Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed] Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed] ''How to…'' papers. Example. [Always peer reviewed] Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed] Letters. [Peer reviewed at the editor''s discretion] International scope IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.
期刊最新文献
High Prevalence of Unrecorded Stage 3 Chronic Kidney Disease in Australia, Brazil, Canada, England, and Spain: The Multinational, Observational REVEAL-CKD Study Influencing Factors for Depression and Depression Aggravation in Hospitalized Elderly Patients With Chronic Heart Failure Blood Urea Nitrogen to Albumin Ratio Was Associated With Mortality in Critically Ill Septic Patients: A Multicenter Retrospective Propensity–Adjusted Analysis Affordability of Original and Generic Antihypertensive Drugs Under the National Centralized Drug Procurement Policy and Basic Medical Insurance System: A Cross-Sectional Survey in Xi’an, China Guidelines for Returning to Dance Following Concussion: Adaptations From Sport Concussion Literature
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1